---
title: "Mineralys Therapeutics, Inc. (MLYS) Receives a Buy from Wells Fargo"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279131533.md"
description: "Mineralys Therapeutics, Inc. (MLYS) received a Buy rating from Wells Fargo, with a price target of $55.00. The stock closed at $26.19. Analyst Mohit Bansal has an average return of 9.2% and a 55.80% success rate. The overall analyst consensus for MLYS is a Strong Buy, with an average price target of $53.60, indicating a potential upside of 104.66%. Bank of America Securities also assigned a Buy rating with a $51.00 price target."
datetime: "2026-03-14T16:36:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279131533.md)
  - [en](https://longbridge.com/en/news/279131533.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279131533.md)
---

# Mineralys Therapeutics, Inc. (MLYS) Receives a Buy from Wells Fargo

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Mineralys Therapeutics, Inc., with a price target of $55.00. The company’s shares closed yesterday at $26.19.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Bansal covers the Healthcare sector, focusing on stocks such as Merck & Company, AbbVie, and Amgen. According to TipRanks, Bansal has an average return of 9.2% and a 55.80% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mineralys Therapeutics, Inc. with a $53.60 average price target, representing a 104.66% upside. In a report released yesterday, Bank of America Securities also assigned a Buy rating to the stock with a $51.00 price target.

### Related Stocks

- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [MLYS.US](https://longbridge.com/en/quote/MLYS.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)
- [Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive](https://longbridge.com/en/news/282775123.md)
- [Wells Fargo Reports First Quarter 2026 Financial Results | WFC Stock News](https://longbridge.com/en/news/282674105.md)
- [Wells Fargo CEO speaking on conference call](https://longbridge.com/en/news/282715238.md)
- [Wells Fargo CFO on private credit exposure: we're quite comfortable with sort of the risk that we have in that underlying portfolio](https://longbridge.com/en/news/282685089.md)